Vol. 2 No. 5 (2022)
Reimbursement Recommendations

Ripretinib (Qinlock)

Published May 16, 2022

Key Messages

  • CADTH recommends that Qinlock be reimbursed by public drug plans for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) if certain conditions are met.
  • Qinlock should only be covered to treat adult patients with GIST that has spread beyond the initial tumour site (advanced disease) and whose tumours have progressed while on treatment with imatinib, sunitinib, and regorafenib (which belong to the same drug class as Qinlock), or who could not take these drugs due to side effects.
  • Qinlock should only be reimbursed if the drug is prescribed without any other anticancer drugs by a clinician with expertise in the treatment of GIST, and if the cost of Qinlock is reduced.